Complete Filing Data
Innventure, Inc. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $483.68 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Innventure, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income * | -$293.3M | -$30.8M | |
| Selling And Marketing Expense | $9.6M | $3.2M | |
| Revenue From Contract With Customer Excluding Assessed Tax | $2.1M | $1.1M | |
| Research And Development Expense | $25.0M | $4.0M | |
| Other Comprehensive Income Loss Net Of Tax | -$2.2M | $0.00 | |
| Operating Income Loss | -$464.7M | -$23.7M | |
| Nonoperating Income Expense | -$24.1M | -$7.3M | |
| Interest Income Expense Nonoperating Net | -$9.7M | -$1.2M | |
| Income Tax Expense Benefit | -$13.5M | $0.00 | |
| Income Loss From Equity Method Investments | -$12.6M | -$632.0K | |
| General And Administrative Expense | $66.7M | $17.6M | |
| Other Nonoperating Income Expense | -$46.0K | $0.00 | |
| Cost Of Goods And Services Sold | $18.8M | $0.00 | |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$477.5M | -$31.0M | |
| Comprehensive Income Net Of Tax | -$295.5M | -$30.8M | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$488.8M | -$31.0M | |
| Net Income Loss Attributable To Noncontrolling Interest | -$182.0M | -$139.0K | |
| Deferred Income Tax Expense Benefit | -$13.5M | $0.00 | |
| Goodwill Impairment Loss | $346.6M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$28.3M | -$84.2M | -$143.0M | -$61.8M | -$2.2M | -$7.3M | -$5.2M | -$18.9M | $4.6M | -$3.6M |
| Selling And Marketing Expense | $2.5M | $2.2M | $2.1M | $2.0M | $1.6M | $1.4M | $1.2M | $696.0K | ||
| Revenue From Contract With Customer Excluding Assessed Tax | $534.0K | $476.0K | $224.0K | $456.0K | $317.0K | $223.0K | $224.0K | $274.0K | ||
| Research And Development Expense | $6.2M | $6.1M | $6.3M | $5.3M | $2.5M | $1.8M | $1.7M | $1.2M | ||
| Other Comprehensive Income Loss Net Of Tax | $281.0K | $189.0K | -$2.4M | $909.0K | -$2.4M | $0.00 | $0.00 | $0.00 | ||
| Operating Income Loss | -$29.2M | -$142.6M | -$261.2M | -$40.3M | -$13.7M | -$11.3M | -$10.5M | -$5.7M | ||
| Nonoperating Income Expense | -$9.1M | -$921.0K | $6.1M | -$33.1M | $6.0M | -$28.0K | $3.0M | -$13.2M | ||
| Interest Income Expense Nonoperating Net | -$3.4M | -$2.6M | -$1.5M | -$1.1M | -$852.0K | -$43.0K | -$405.0K | -$364.0K | ||
| Income Tax Expense Benefit | -$3.6M | -$2.2M | -$1.4M | -$3.3M | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Income Loss From Equity Method Investments | -$1.6M | -$1.9M | -$6.8M | -$902.0K | $109.0K | $779.0K | $5.0K | -$673.0K | ||
| General And Administrative Expense | $16.9M | $18.6M | $19.7M | $29.7M | $9.1M | $8.4M | $7.9M | $4.1M | ||
| Other Nonoperating Income Expense | -$21.0K | -$64.0K | $21.0K | -$57.0K | -$64.0K | $0.00 | $0.00 | $0.00 | ||
| Cost Of Goods And Services Sold | $4.1M | $2.9M | $184.0K | $3.8M | $777.0K | $0.00 | $0.00 | $0.00 | ||
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$34.5M | -$141.1M | -$256.1M | -$69.2M | -$10.0M | -$11.3M | -$7.5M | -$18.9M | ||
| Comprehensive Income Net Of Tax | -$28.1M | -$84.0M | -$145.4M | -$60.8M | -$4.6M | -$7.3M | -$5.2M | -$18.9M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$38.3M | -$143.5M | -$255.1M | -$73.4M | -$7.6M | -$11.3M | -$7.5M | |||
| Net Income Loss Attributable To Noncontrolling Interest | -$6.4M | -$8.3M | -$5.4M | -$45.0K | ||||||
| Deferred Income Tax Expense Benefit | -$1.9M | -$3.3M | $0.00 | |||||||
| Goodwill Impairment Loss | $0.00 | $113.3M | $233.2M | $0.00 | $0.00 | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity * | $204.2M | $425.5M | -$20.0M | -$11.2M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $65.4M | $11.1M | $2.6M | $7.5M |
| Noncontrolling Interest Increase From Subsidiary Equity Issuance | $337.0K | |||
| Unrealized Gain Loss On Financial Liabilities | $16.1M | $766.0K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $54.3M | -$5.0M | ||
| Amortization Of Debt Discount Premium | $6.6M | $487.0K | ||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | $22.6M | $10.6M | $15.9M | |
| Temporary Equity Accretion To Redemption Value | $0.00 | $5.4M | ||
| Issuance Of Noncontrolling Interest For Notes Payable | $0.00 | $0.00 | ||
| Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock | -$5.4M | |||
| Transfer To Investments | $4.4M | $0.00 | ||
| Retained Earnings Accumulated Deficit | -$371.6M | -$78.3M | -$64.3M | |
| Property Plant And Equipment Net | $1.9M | $1.4M | $637.0K | |
| Prepaid Expense And Other Assets Current | $3.2M | $3.2M | $487.0K | |
| Patent Installment Payable Noncurrent | $12.4M | $12.4M | $13.1M | |
| Patent Installment Payable Current | $700.0K | $1.2M | $775.0K | |
| Other Receivables Net Current | $11.8M | $4.5M | $2.6M | |
| Other Liabilities Noncurrent | $556.0K | $355.0K | $683.0K | |
| Other Liabilities Current | $682.0K | $317.0K | $253.0K | |
| Other Assets Noncurrent | $1.4M | $766.0K | $1.1M | |
| Other Accrued Liabilities Current | $7.4M | $2.5M | $1.0M | |
| Minority Interest | $279.5M | $340.8M | $1.6M | |
| Long Term Investments | $28.7M | $28.7M | $14.2M | |
| Liabilities Current | $76.3M | $69.3M | $8.2M | |
| Liabilities And Stockholders Equity | $599.2M | $905.3M | $21.6M | |
| Liabilities | $115.5M | $139.0M | $29.4M | |
| Assets Current | $83.2M | $24.3M | $5.7M | |
| Assets | $599.2M | $905.3M | $21.6M | |
| Accrued Employee Benefits Current | $11.3M | $9.3M | $3.8M | |
| Inventory Net | $1.6M | $5.2M | $0.00 | |
| Debt Instrument Noncash Debt Discount And Embedded Derivative | $0.00 | $1.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $190.8M | $218.6M | $261.5M | -$11.7M | -$10.5M | -$18.0M | -$14.4M | -$14.3M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $14.1M | $12.0M | $1.4M | $2.1M | $2.2M | $4.1M | ||||
| Noncontrolling Interest Increase From Subsidiary Equity Issuance | $6.9M | $4.1M | $3.1M | $7.3M | $3.5M | $101.0K | $104.0K | |||
| Unrealized Gain Loss On Financial Liabilities | -$4.1M | $7.2M | $16.4M | -$20.9M | $0.00 | $0.00 | -$478.0K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$9.7M | $11.1M | -$418.0K | |||||||
| Amortization Of Debt Discount Premium | $510.0K | $248.0K | $230.0K | |||||||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | $15.4M | $15.0M | $13.8M | $23.9M | $16.3M | |||||
| Temporary Equity Accretion To Redemption Value | $0.00 | $0.00 | $4.4M | |||||||
| Issuance Of Noncontrolling Interest For Notes Payable | $0.00 | $0.00 | $7.3M | |||||||
| Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock | $7.2M | $362.0K | $4.4M | -$10.1M | $7.5M | $458.0K | ||||
| Transfer To Investments | $4.4M | $0.00 | $0.00 | |||||||
| Retained Earnings Accumulated Deficit | -$333.8M | -$305.5M | -$221.3M | -$91.0M | ||||||
| Property Plant And Equipment Net | $2.2M | $2.0M | $2.2M | $1.2M | ||||||
| Prepaid Expense And Other Assets Current | $2.7M | $2.5M | $3.3M | $1.9M | ||||||
| Patent Installment Payable Noncurrent | $12.4M | $12.4M | $12.4M | $13.1M | ||||||
| Patent Installment Payable Current | $700.0K | $700.0K | $700.0K | $525.0K | ||||||
| Other Receivables Net Current | $7.5M | $4.2M | $124.0K | $210.0K | ||||||
| Other Liabilities Noncurrent | $660.0K | $176.0K | $260.0K | $501.0K | ||||||
| Other Liabilities Current | $660.0K | $380.0K | $340.0K | $288.0K | ||||||
| Other Assets Noncurrent | $1.5M | $652.0K | $707.0K | $930.0K | ||||||
| Other Accrued Liabilities Current | $3.2M | $2.6M | $3.1M | $1.9M | ||||||
| Minority Interest | $215.8M | $207.5M | $264.2M | $13.1M | ||||||
| Long Term Investments | $31.2M | $32.4M | $33.7M | $32.4M | ||||||
| Liabilities Current | $82.5M | $72.3M | $47.3M | $41.6M | ||||||
| Liabilities And Stockholders Equity | $556.5M | $556.0M | $660.4M | $55.7M | ||||||
| Liabilities | $149.9M | $129.9M | $105.9M | $55.5M | ||||||
| Assets Current | $32.3M | $21.1M | $10.3M | $21.2M | ||||||
| Assets | $556.5M | $556.0M | $660.4M | $55.7M | ||||||
| Accrued Employee Benefits Current | $12.2M | $10.6M | $11.2M | $7.6M | ||||||
| Inventory Net | $6.4M | $6.6M | $5.2M | $2.8M | ||||||
| Debt Instrument Noncash Debt Discount And Embedded Derivative | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Share Based Compensation | $27.9M | $910.0K | |
| Proceeds From Minority Shareholders | $71.4M | $337.0K | |
| Proceeds From Issuance Or Sale Of Equity | $12.7M | $16.0M | |
| Payments To Acquire Property Plant And Equipment | $1.4M | $645.0K | |
| Net Cash Provided By Used In Operating Activities | -$80.7M | -$19.5M | |
| Net Cash Provided By Used In Investing Activities | -$4.1M | -$4.7M | |
| Net Cash Provided By Used In Financing Activities | $139.1M | $19.2M | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $11.7M | $218.0K | |
| Increase Decrease In Other Accrued Liabilities | -$480.0K | $1.2M | |
| Increase Decrease In Employee Related Liabilities | $1.7M | $3.2M | |
| Increase Decrease In Accounts Payable | -$1.4M | $9.0K | |
| Proceeds From Sale Of Equity Securities Fv Ni | $0.00 | $708.0K | |
| Increase Decrease In Inventories | -$3.6M | $0.00 | |
| Increase Decrease In Other Operating Liabilities | -$358.0K | -$155.0K | |
| Increase Decrease In Other Noncurrent Assets | $61.0K | $218.0K | |
| Increase Decrease In Deferred Compensation | -$921.0K | $0.00 | |
| Increase Decrease In Accounts Receivable | $811.0K | $0.00 | |
| Depreciation Amortization And Accretion Net | $22.5M | $8.0K | |
| Payments For Advance To Affiliate | $0.00 | $0.00 | |
| Proceeds From Trust Business Combination | $0.00 | $11.3M | $0.00 |
| Payments To Acquire Available For Sale Securities Debt | $2.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q4 2024 | Q1 2024 |
|---|---|---|---|
| Share Based Compensation | $5.8M | $16.3M | $396.0K |
| Proceeds From Minority Shareholders | $4.9M | $4.2M | $3.5M |
| Proceeds From Issuance Or Sale Of Equity | $3.7M | $15.4M | $7.1M |
| Payments To Acquire Property Plant And Equipment | $917.0K | $266.0K | $640.0K |
| Net Cash Provided By Used In Operating Activities | -$14.7M | -$29.2M | -$7.4M |
| Net Cash Provided By Used In Investing Activities | -$3.3M | $6.8M | -$3.2M |
| Net Cash Provided By Used In Financing Activities | $8.2M | $33.5M | $10.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $122.0K | $1.3M | $136.0K |
| Increase Decrease In Other Accrued Liabilities | $565.0K | -$484.0K | $488.0K |
| Increase Decrease In Employee Related Liabilities | $1.9M | $1.7M | $1.3M |
| Increase Decrease In Accounts Payable | $1.6M | -$11.2M | $1.2M |
| Proceeds From Sale Of Equity Securities Fv Ni | $0.00 | ||
| Increase Decrease In Inventories | $42.0K | $2.4M | $0.00 |
| Increase Decrease In Other Operating Liabilities | -$73.0K | -$77.0K | -$68.0K |
| Increase Decrease In Other Noncurrent Assets | $0.00 | ||
| Increase Decrease In Deferred Compensation | -$442.0K | $1.2M | $0.00 |
| Increase Decrease In Accounts Receivable | -$46.0K | $166.0K | $0.00 |
| Depreciation Amortization And Accretion Net | $5.5M | $5.5M | $0.00 |
| Payments For Advance To Affiliate | $0.00 | $4.2M | $2.5M |
| Proceeds From Trust Business Combination | $11.3M | ||
| Payments To Acquire Available For Sale Securities Debt | $2.3M | $0.00 | $0.00 |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 54.4M | |
| Earnings Per Share Basic | $-5.39 | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Earnings Per Share Diluted | $-5.39 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 55.8M | 52.5M | 46.3M | 44.0M | 10.9M | 10.9M |
| Earnings Per Share Basic | $-0.51 | $-1.60 | $-3.10 | $-1.41 | $-0.94 | $-0.84 |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |||
| Earnings Per Share Diluted | $-0.51 | $-1.60 | $-3.10 | $-1.41 | $-0.94 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2023 |
|---|---|---|
| Costs And Expenses | $466.8M | $24.8M |
| Interest Paid Net | $0.00 | $297.0K |
| Noncash Interest Income | $394.0K | $0.00 |
| Payment Of Patent Installment | $525.0K | $0.00 |
| Paid In Kind Interest | $336.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Costs And Expenses | $29.7M | $143.1M | $261.4M | $40.8M | $14.0M | $11.5M | $10.8M | $6.0M |
| Interest Paid Net | $1.1M | $991.0K | $55.0K | |||||
| Noncash Interest Income | $91.0K | $106.0K | $0.00 | |||||
| Payment Of Patent Installment | $525.0K | $0.00 | $0.00 | |||||
| Paid In Kind Interest | $69.0K |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.